Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a report released on Saturday, Wall Street Zen reports.
Other equities analysts have also issued reports about the company. Wedbush reiterated an “outperform” rating on shares of Larimar Therapeutics in a research report on Tuesday, November 10th. Leerink Partners began coverage on Larimar Therapeutics in a research report on Monday, September 14th. They issued an “outperform” rating and a $13.00 target price for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Larimar Therapeutics in a research report on Thursday, October 15th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $10.33.
View Our Latest Research Report on Larimar Therapeutics
Larimar Therapeutics Price Performance
Shares of LRMR stock opened at $3.02 on Friday. The business has a 50-day moving average price of $2.93 and a two-hundred day moving average price of $3.76. Larimar Therapeutics has a 12-month low of $1.91 and a 12-month high of $6.42. The firm has a market cap of $313.73 million, a P/E ratio of -1.55 and a beta of 0.73.
Insider Activity
In other news, CFO Michael Celano purchased 18,460 shares of the business’s stock in a transaction on Wednesday, November 11th. The shares were acquired at an average price of $2.71 per share, with a total value of $50,026.60. Following the acquisition, the chief financial officer directly owned 234,245 shares in the company, valued at approximately $634,803.95. The trade was a 8.55% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Carole Ben-Maimon acquired 18,050 shares of the firm’s stock in a transaction on Wednesday, November 11th. The stock was purchased at an average price of $2.77 per share, for a total transaction of $49,998.50. Following the transaction, the chief executive officer directly owned 386,326 shares of the company’s stock, valued at approximately $1,070,123.02. This trade represents a 4.90% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders acquired 140,810 shares of company stock worth $381,955. 4.00% of the stock is currently owned by corporate insiders.
Institutional Trading of Larimar Therapeutics
Institutional investors have recently modified their holdings of the company. Integrated Wealth Concepts LLC purchased a new position in Larimar Therapeutics during the 2nd quarter valued at about $27,000. Pallas Capital Advisors LLC bought a new position in Larimar Therapeutics during the 2nd quarter valued at approximately $31,000. HB Wealth Management LLC purchased a new stake in Larimar Therapeutics in the 2nd quarter worth approximately $49,000. Sei Investments Co. lifted its holdings in Larimar Therapeutics by 54.5% in the 1st quarter. Sei Investments Co. now owns 16,336 shares of the company’s stock worth $74,000 after buying an additional 5,763 shares during the period. Finally, The Manufacturers Life Insurance Company purchased a new stake in Larimar Therapeutics in the 2nd quarter worth approximately $60,000. 91.92% of the stock is currently owned by hedge funds and other institutional investors.
Key Headlines Impacting Larimar Therapeutics
Here are a few of the latest headlines about LRMR:
- Positive Sentiment: CEO Carole Ben-Maimon, CFO Michael Celano, COO John B. Jr. Harlow, insider Gopi Shankar, and directors Frank Thomas and Joseph Truitt together purchased 52,810 shares for roughly $195,000. Director Thomas Hamilton separately bought 70,000 shares for $186,900. Insider purchase report Hamilton SEC filing
- Neutral Sentiment: The supplied coverage also notes H.C. Wainwright maintained a Buy rating; no rating change or fresh price-moving catalyst was reported. Analyst rating report
About Larimar Therapeutics
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Bala Cynwyd, Pennsylvania, focused on developing treatments for rare diseases. Its lead drug candidate is nomlabofusp, formerly known as CTI-1601, an engineered fusion protein designed to deliver frataxin to mitochondria. Nomlabofusp is being developed to treat Friedreich’s ataxia, a rare, inherited neurodegenerative disorder associated with insufficient frataxin. Larimar’s approach uses a cell-penetrating peptide to transport frataxin into cells and mitochondria, with the goal of addressing an underlying cause of the disease rather than only treating its symptoms.
Further Reading
- Five stocks we like better than Larimar Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
